What does PHARM@21 do?

PHARM@21 is a landscaping contractor in Aalst. Private Limited, started on 6 October 2005, 1 establishment.

What is the address of PHARM@21?

The registered office of PHARM@21 is located at Populierestraat 80, 9310 Aalst.

Is PHARM@21 still active?

Yes. According to the CBE (30 October 2026) PHARM@21 is active, legal situation “Normale toestand”, started on 6 October 2005.

Is PHARM@21 registered on Peppol?

Yes, PHARM@21 is registered on the Peppol network with ID 0208:0876529018.

What is the enterprise number of PHARM@21?

The enterprise number of PHARM@21 is BE0876529018.

When was PHARM@21 founded?

PHARM@21 was founded on 6 October 2005.

Who are the directors of PHARM@21?

According to the 2025 annual accounts, the directors of PHARM@21 are: TINA VLAEMINCK, JORIS VAN BREMPT.

Is PHARM@21 a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 October 2005; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARM@21 make in 2025?

PHARM@21 posted a profit after taxes of € 51,752 in financial year 2025.

What is the revenue of PHARM@21?

As a small company, PHARM@21 is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 222,925.

PHARM@21 (Private Limited) - Aalst - BE0876529018

Dossier PHARM@21, printed on 30 October 2026 from databakkes.be/en/0876529018/pharm-21. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARM@21 from Aalst, company number BE0876529018, closed financial year 2025 with a result of € 51,752 after tax. For that financial year PHARM@21 recorded a gross margin of € 222,925 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 88,503 to € 51,752. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 27, 2025.

What it is worth Growing

€ 1.1 million

▲ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 51,752

▼ 42% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 10,964

▼ 95% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.1 million.

People and assets in 2025

Vehicles and equipment

€ 1,283

▼ 2% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.5 million

▲ 13% vs 2024

€ 142,678 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 430,797

▼ 29% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 2,986

▼ 15% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 193,037 Gross margin 2022: € 193,037 First fiscal year in the series	€ 152,603 Gross margin 2023: € 152,603 ▼ 21% vs 2022 (€ 193,037) Unfavourable step	€ 187,225 Gross margin 2024: € 187,225 ▲ 23% vs 2023 (€ 152,603) Favourable step	€ 222,925 Gross margin 2025: € 222,925 ▲ 19% vs 2024 (€ 187,225) Favourable step	▲ 19%
Profit after taxes	€ 91,826 Profit after taxes 2022: € 91,826 First fiscal year in the series	€ 72,896 Profit after taxes 2023: € 72,896 ▼ 21% vs 2022 (€ 91,826) Unfavourable step	€ 88,503 Profit after taxes 2024: € 88,503 ▲ 21% vs 2023 (€ 72,896) Favourable step	€ 51,752 Profit after taxes 2025: € 51,752 ▼ 42% vs 2024 (€ 88,503) Unfavourable step	▼ 42%
Equity	€ 931,577 Equity 2022: € 931,577 First fiscal year in the series	€ 998,273 Equity 2023: € 998,273 ▲ 7% vs 2022 (€ 931,577) Favourable step	€ 1,086,776 Equity 2024: € 1,086,776 ▲ 9% vs 2023 (€ 998,273) Favourable step	€ 1,144,728 Equity 2025: € 1,144,728 ▲ 5% vs 2024 (€ 1,086,776) Favourable step	▲ 5%
Total debts	€ 1,067,119 Total debts 2022: € 1,067,119 First fiscal year in the series	€ 1,683,924 Total debts 2023: € 1,683,924 ▲ 58% vs 2022 (€ 1,067,119) Unfavourable step	€ 2,011,709 Total debts 2024: € 2,011,709 ▲ 19% vs 2023 (€ 1,683,924) Unfavourable step	€ 2,062,175 Total debts 2025: € 2,062,175 ▲ 3% vs 2024 (€ 2,011,709) Unfavourable step	▲ 3%
Cash	€ 9,303 Cash 2022: € 9,303 First fiscal year in the series	€ 134,451 Cash 2023: € 134,451 ▲ € 125,147 vs 2022 (€ 9,303) Favourable step	€ 230,942 Cash 2024: € 230,942 ▲ 72% vs 2023 (€ 134,451) Favourable step	€ 10,964 Cash 2025: € 10,964 ▼ 95% vs 2024 (€ 230,942) Unfavourable step	▼ 95%
Land & buildings	€ 876,918 Land & buildings 2022: € 876,918 First fiscal year in the series	€ 1,426,228 Land & buildings 2023: € 1,426,228 ▲ 63% vs 2022 (€ 876,918) Unchanged	€ 1,596,835 Land & buildings 2024: € 1,596,835 ▲ 12% vs 2023 (€ 1,426,228) Unchanged	€ 2,078,997 Land & buildings 2025: € 2,078,997 ▲ 30% vs 2024 (€ 1,596,835) Unchanged	▲ 30%
Retained profit	€ 925,377 Retained profit 2022: € 925,377 First fiscal year in the series	€ 998,273 Retained profit 2023: € 998,273 ▲ 8% vs 2022 (€ 925,377) Favourable step	€ 1,086,776 Retained profit 2024: € 1,086,776 ▲ 9% vs 2023 (€ 998,273) Favourable step	€ 1,138,528 Retained profit 2025: € 1,138,528 ▲ 5% vs 2024 (€ 1,086,776) Favourable step	▲ 5%
Bank debt	€ 764,902 Bank debt 2022: € 764,902 First fiscal year in the series	€ 1,300,272 Bank debt 2023: € 1,300,272 ▲ 70% vs 2022 (€ 764,902) Unfavourable step	€ 1,339,945 Bank debt 2024: € 1,339,945 ▲ 3% vs 2023 (€ 1,300,272) Unfavourable step	€ 1,511,772 Bank debt 2025: € 1,511,772 ▲ 13% vs 2024 (€ 1,339,945) Unfavourable step	▲ 13%
Balance sheet total	€ 1,998,696 Balance sheet total 2022: € 1,998,696 First fiscal year in the series	€ 2,682,197 Balance sheet total 2023: € 2,682,197 ▲ 34% vs 2022 (€ 1,998,696) Unchanged	€ 3,098,485 Balance sheet total 2024: € 3,098,485 ▲ 16% vs 2023 (€ 2,682,197) Unchanged	€ 3,206,903 Balance sheet total 2025: € 3,206,903 ▲ 3% vs 2024 (€ 3,098,485) Unchanged	▲ 3%

Key figures of PHARM@21, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to PHARM@21?

What happened at PHARM@21 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 27, 2025 New annual accounts for financial year 2025: profit of € 51,752 (▼ 42% vs 2024). filed late Source: NBB ↗
Apr 4, 2006 New establishment in Aalst. KBO
Oct 6, 2005 Start of the company according to the CBE. KBO

In short

From € 91,826 profit in 2022 to € 51,752 profit in 2025.

Paid € 112,628 in corporate taxes since 2022.

Best year ever: 2022, with € 91,826 profit.

Original PDFs at the National Bank ↗

Management

TINA VLAEMINCK

JORIS VAN BREMPT

PHARM@21

APOTEEK KELLES 100%

Behind PHARM@21 are TINA VLAEMINCK and JORIS VAN BREMPT. It owns 100% of APOTEEK KELLES itself.

Directors

According to the 2025 annual accounts

TINA VLAEMINCK

Director

Also active at: APOBELLE

JORIS VAN BREMPT

Director

Also active at: APOBELLE

Establishments

Establishment units

Physical locations of this company

Registered office

Populierestraat 80

9310 Aalst

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0876.529.018

VAT number

BE 0876.529.018

Registered office

Populierestraat 80, 9310 Aalst

Names & denominations

PHARM@21

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 October 2005

Peppol

Active · Active since 30 Aug 2023

Activities · NACE

Landschapsverzorging

Detailhandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in cosmetica en toiletartikelen

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige activiteiten op het gebied van menselijke gezondheidszorg, neg

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARM@21

Warning lights

Financials

What happened to PHARM@21?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions